Plexus director sells 500 shares under 10b5-1 plan

Plexus Corp director Karen Marie Rapp reported an open-market sale of 500 shares of common stock at $195.59 per share on February 27, 2026.

Accepted by SEC EDGAR 03/02/2026 - 04:41 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Plexus Corp director Karen Marie Rapp reported an open-market sale of 500 shares of common stock at $195.59 per share on February 27, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2024.

After this transaction, Rapp directly holds 8,535 Plexus shares, reflecting a modest reduction in her direct ownership.

Insider Trade Summary

Net Seller: 500 shares

Net Sell 1 txn

Insider Rapp Karen Marie

Role Director

Sold 500 shs ($98K)

Share of Position Sold 5.5%

Type	Security	Shares	Price	Value
Sale	Common Stock, $.01 par value	500	$195.59	$98K

Holdings After Transaction: Common Stock, $.01 par value — 8,535 shares (Direct)

Holdings Before and After: Common Stock, $.01 par value, 9,035 to 8,535 shares (Direct)

Other Insiders: 9 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

F1. Shares were sold pursuant to a Rule 10b5-1 plan adopted on February 28, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Plexus Corp (PLXS) report for Karen Marie Rapp?

Plexus Corp reported that director Karen Marie Rapp sold 500 shares of common stock. The open-market sale occurred on February 27, 2026 at $195.59 per share, under a pre-established Rule 10b5-1 trading plan adopted in February 2024.

At what price did Karen Marie Rapp sell Plexus (PLXS) shares?

Karen Marie Rapp sold her Plexus shares at $195.59 per share. This price applied to 500 shares of common stock sold in an open-market transaction reported on February 27, 2026, as disclosed in the Form 4 insider trading report.

How many Plexus (PLXS) shares does Karen Marie Rapp own after the sale?

After the reported sale, Karen Marie Rapp directly owns 8,535 Plexus shares. This reflects her holdings following the February 27, 2026 open-market sale of 500 common shares reported in the Form 4 filing with the Securities and Exchange Commission.

Was the Plexus (PLXS) insider sale by Karen Marie Rapp under a 10b5-1 plan?

Yes. The shares sold by Karen Marie Rapp were pursuant to a Rule 10b5-1 trading plan. The plan was adopted on February 28, 2024, allowing pre-scheduled share sales independent of day-to-day market conditions or subsequent personal decisions.

What type of security did Karen Marie Rapp sell in Plexus (PLXS)?

Karen Marie Rapp sold Plexus common stock with a par value of $0.01 per share. The Form 4 shows a non-derivative open-market sale of 500 common shares, executed at a price of $195.59 per share on February 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rapp Karen Marie

(Last)

(First)

(Middle)

ONE PLEXUS WAY

(Street)

NEENAH

54956

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PLEXUS CORP [ PLXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $.01 par value	02/27/2026		S⁽¹⁾		500	D	$195.59	8,535	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares were sold pursuant to a Rule 10b5-1 plan adopted on February 28, 2024.

Remarks:

	/s/ Karen Rapp, by Kate A. Gitter, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR